Kymera Therapeutics Quarterly Income Statement
NASDAQ: KYMRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Kymera Therapeutics revenue and earnings
In the quarter ended Jun 30, 2026, Kymera Therapeutics generated $65.0 million in revenue, up 466.4% from the same quarter a year earlier. Kymera Therapeutics reported a net loss of $61.2 million, compared with a loss of $76.6 million a year earlier. Gross margin was 0.0% (flat year over year) and operating margin -116.3%.
Diluted earnings per share came in at -$0.62.
Summary generated from market data by MetaCap's automated system. Methodology
Kymera Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.00M | 34.37M | 2.87M | 2.76M | 11.48M | 22.10M | 7.39M | 3.74M | 25.65M | 10.29M | 47.88M | 4.73M |
| Revenue growth (YoY) | +466.40% | +55.50% | -61.18% | -26.12% | -55.26% | +114.83% | -84.56% | -20.88% | +55.33% | +8.67% | +196.70% | -50.50% |
| Cost of Revenue | 65.00M | 34.37M | 2.87M | 2.76M | 11.48M | 22.10M | 7.39M | 3.74M | 25.65M | 10.29M | — | — |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — |
| Operating Expenses | 140.61M | 118.52M | 100.77M | 95.28M | 96.03M | 96.53M | 88.15M | 75.86M | 76.58M | 68.12M | 67.20M | 62.24M |
| Research & Development | 119.48M | 98.16M | 83.83M | 74.09M | 78.39M | 80.25M | 71.82M | 60.41M | 59.20M | 48.82M | 52.97M | 48.12M |
| Operating Income | -75.61M | -84.15M | -97.90M | -92.52M | -84.56M | -74.43M | -80.75M | -72.12M | -50.92M | -57.83M | -19.31M | -57.51M |
| Other Income (Expense) | 14.40M | 14.92M | 10.91M | 10.35M | 7.94M | 8.85M | 10.00M | 9.64M | 8.86M | 9.27M | 4.94M | 4.64M |
| Income Tax | — | — | — | — | — | — | — | — | — | — | — | 100.00K |
| Net Income | -61.21M | -69.23M | -86.98M | -82.17M | -76.61M | -65.58M | -70.75M | -62.49M | -42.06M | -48.56M | -14.37M | -52.87M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.62 | -0.71 | -0.98 | -0.94 | -0.95 | -0.82 | -0.89 | -0.82 | -0.58 | -0.69 | -0.25 | -0.90 |
| EPS (Diluted) | -0.62 | -0.71 | -0.98 | -0.94 | -0.95 | -0.82 | -0.89 | -0.82 | -0.58 | -0.69 | -0.25 | -0.90 |
| Shares Outstanding (Basic) | 98.18M | 97.53M | — | 87.30M | 80.45M | 80.15M | — | 76.13M | 73.06M | 70.77M | — | 58.42M |
| Shares Outstanding (Diluted) | 98.18M | 97.53M | — | 87.30M | 80.45M | 80.15M | — | 76.13M | 73.06M | 70.77M | — | 58.42M |
| EBITDA | -73.58M | -82.13M | -95.86M | -90.37M | -82.47M | -72.38M | -78.77M | -70.14M | -48.99M | -56.37M | -18.42M | -56.61M |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
| Operating Margin | -116.32% | -244.88% | -3411.01% | -3347.36% | -736.82% | -336.77% | -1092.17% | -1927.93% | -198.54% | -562.18% | -40.33% | -1216.35% |
| Net Margin | -94.17% | -201.47% | -3030.70% | -2973.05% | -667.60% | -296.75% | -956.88% | -1670.33% | -163.98% | -472.02% | -30.01% | -1118.17% |
This table shows 12 quarterly periods of Kymera Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 17 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow KYMR's reporting calendar. What is a income statement?